{"DataElement":{"publicId":"6031097","version":"1","preferredName":"Lung Cancer AJCC Edition 8 Disease Stage","preferredDefinition":"Stage group based on the combination of T, N, and M categories and relevant prognostic factors for lung cancer, using AJCC Ed. 8 criteria.","longName":"LUNG_AJC8_DZ_STG","context":"NCI Standards","contextVersion":"1","DataElementConcept":{"publicId":"3745004","version":"2","preferredName":"Lung Neoplasm Stage Grouping","preferredDefinition":"One of a pair of viscera occupying the pulmonary cavities of the thorax, the organs of respiration in which aeration of the blood takes place. As a rule, the right lung is slightly larger than the left and is divided into three lobes (an upper, a middle, and a lower or basal), while the left has but two lobes (an upper and a lower or basal). Each lung is irregularly conical in shape, presenting a blunt upper extremity (the apex), a concave base following the curve of the diaphragm, an outer convex surface (costal surface), an inner or mediastinal surface (mediastinal surface), a thin and sharp anterior border, and a thick and rounded posterior border._A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias._An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage.","longName":"2206550v1.0:2230143v1.0","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"2206550","version":"1","preferredName":"Lung Neoplasm","preferredDefinition":"One of a pair of viscera occupying the pulmonary cavities of the thorax, the organs of respiration in which aeration of the blood takes place. As a rule, the right lung is slightly larger than the left and is divided into three lobes (an upper, a middle, and a lower or basal), while the left has but two lobes (an upper and a lower or basal). Each lung is irregularly conical in shape, presenting a blunt upper extremity (the apex), a concave base following the curve of the diaphragm, an outer convex surface (costal surface), an inner or mediastinal surface (mediastinal surface), a thin and sharp anterior border, and a thick and rounded posterior border. SYN pulmo.:(NEE-o-PLAY-zha) Abnormal and uncontrolled cell growth.","longName":"C12468:C3262","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lung","conceptCode":"C12468","definition":"One of a pair of viscera occupying the pulmonary cavities of the thorax, the organs of respiration in which aeration of the blood takes place. As a rule, the right lung is slightly larger than the left and is divided into three lobes (an upper, a middle, and a lower or basal), while the left has two lobes (an upper and a lower or basal). Each lung is irregularly conical in shape, presenting a blunt upper extremity (the apex), a concave base following the curve of the diaphragm, an outer convex surface (costal surface), an inner or mediastinal surface (mediastinal surface), a thin and sharp anterior border, and a thick and rounded posterior border.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm","conceptCode":"C3262","definition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0428-F968-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2230143","version":"1","preferredName":"Stage Grouping","preferredDefinition":"Stage Grouping; an assessment based on the combined evaluation of the patient's T stage, M stage, and N stage. (caDSR)","longName":"C38027","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage Grouping","conceptCode":"C38027","definition":"An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F752037A-4CC2-36A8-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-05-18","modifiedBy":"ONEDATA","dateModified":"2005-05-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"85C85DC3-8AB7-2DAF-E053-F662850AF3AE","latestVersionIndicator":"Yes","beginDate":"2013-05-07","endDate":"2014-04-21","createdBy":"TAYLORT","dateCreated":"2019-04-05","modifiedBy":"TAYLORT","dateModified":"2019-04-05","changeDescription":"4/5/19 version 2.0 created for AJCC Ed. 8; tmt.  Retired orphan DEC - created DEC 3745006 for AJCC standards. mc 4/21/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6031062","version":"1","preferredName":"Lung Carcinoma American Joint Committee on Cancer Edition 8 Group Stage","preferredDefinition":"A term that refers to the staging of lung cancer, following the rules of the TNM AJCC v8 classification system. This staging system derives from analyses of the new retrospective and prospective databases of the International Association for the Study of Lung Cancer (IASLC). These databases contain information on patients diagnosed with lung cancer from 1999 to 2010 originating from 35 different databases in 16 countries around the world. This staging system applies to carcinomas of the lung, including non-small cell and small cell carcinomas, and bronchopulmonary carcinoid tumors. It does not apply to sarcomas or other rare tumors of the lung. (from AJCC 8th Ed.)_An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage._The extent of a cancer in the body. Staging is usually based on the size of the tumor, whether lymph nodes contain cancer, and whether the cancer has spread from the original site to other parts of the body.","longName":"6031062v1.0","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"16","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"IA1","valueDescription":"Stage IA1 Lung Cancer AJCC v8","ValueMeaning":{"publicId":"6031088","version":"1","preferredName":"Stage IA1 Lung Cancer AJCC v8","longName":"6031088","preferredDefinition":"Stage IA1 includes: IA1: (T1mi, N0, M0); (T1a, N0, M0). T1mi: Minimally invasive adenocarcinoma: adenocarcinoma (3 cm or less in greatest dimension) with a predominantly lepidic pattern and 5 mm or less invasion in greatest dimension. T1a: Tumor measuring 1 cm or less in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. N0: No regional lymph node metastases. M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IA1 Lung Cancer AJCC v8","conceptCode":"C136471","definition":"Stage IA1 includes: IA1: (T1mi, N0, M0); (T1a, N0, M0). T1mi: Minimally invasive adenocarcinoma: adenocarcinoma (3 cm or less in greatest dimension) with a predominantly lepidic pattern and 5 mm or less invasion in greatest dimension. T1a: Tumor measuring 1 cm or less in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. N0: No regional lymph node metastases. M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E83235F-7A93-751B-E053-F662850AF9DE","latestVersionIndicator":"Yes","beginDate":"2017-11-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"85CCBFAD-D0CB-1C32-E053-F662850A75DF","beginDate":"2017-11-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-05","modifiedBy":"ONEDATA","dateModified":"2019-04-05","deletedIndicator":"No"},{"value":"IA2","valueDescription":"Stage IA2 Lung Cancer AJCC v8","ValueMeaning":{"publicId":"6031086","version":"1","preferredName":"Stage IA2 Lung Cancer AJCC v8","longName":"6031086","preferredDefinition":"Stage IA2 includes: T1b, N0, M0. T1b: Tumor measuring more than 1 cm but 2 cm or less in greatest dimension. N0: No regional lymph node metastases. M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IA2 Lung Cancer AJCC v8","conceptCode":"C136472","definition":"Stage IA2 includes: T1b, N0, M0. T1b: Tumor measuring more than 1 cm but 2 cm or less in greatest dimension. N0: No regional lymph node metastases. M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E83235F-7A6D-751B-E053-F662850AF9DE","latestVersionIndicator":"Yes","beginDate":"2017-11-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"85CCBFAD-D0DF-1C32-E053-F662850A75DF","beginDate":"2017-11-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-05","modifiedBy":"ONEDATA","dateModified":"2019-04-05","deletedIndicator":"No"},{"value":"IA3","valueDescription":"Stage IA3 Lung Cancer AJCC v8","ValueMeaning":{"publicId":"6031084","version":"1","preferredName":"Stage IA3 Lung Cancer AJCC v8","longName":"6031084","preferredDefinition":"Stage IA3 includes: T1c, N0, M0. T1c: Tumor measuring more than 2 cm but 3 cm or less in greatest dimension. N0: No regional lymph node metastases. M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IA3 Lung Cancer AJCC v8","conceptCode":"C136473","definition":"Stage IA3 includes: T1c, N0, M0. T1c: Tumor measuring more than 2 cm but 3 cm or less in greatest dimension. N0: No regional lymph node metastases. M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E83235F-7A47-751B-E053-F662850AF9DE","latestVersionIndicator":"Yes","beginDate":"2017-11-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"85CCBFAD-D0F3-1C32-E053-F662850A75DF","beginDate":"2017-11-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-05","modifiedBy":"ONEDATA","dateModified":"2019-04-05","deletedIndicator":"No"},{"value":"IB","valueDescription":"Stage IB Lung Cancer AJCC v8","ValueMeaning":{"publicId":"6031082","version":"1","preferredName":"Stage IB Lung Cancer AJCC v8","longName":"6031082","preferredDefinition":"Stage IB includes: T2a, N0, M0. T2a: Tumor measuring more than 3 cm but 4 cm or less in greatest dimension. N0: No regional lymph node metastases. M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IB Lung Cancer AJCC v8","conceptCode":"C136474","definition":"Stage IB includes: T2a, N0, M0. T2a: Tumor measuring more than 3 cm but 4 cm or less in greatest dimension. N0: No regional lymph node metastases. M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E83235F-7A21-751B-E053-F662850AF9DE","latestVersionIndicator":"Yes","beginDate":"2017-11-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"85CCBFAD-D107-1C32-E053-F662850A75DF","beginDate":"2017-11-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-05","modifiedBy":"ONEDATA","dateModified":"2019-04-05","deletedIndicator":"No"},{"value":"IIA","valueDescription":"Stage IIA Lung Cancer AJCC v8","ValueMeaning":{"publicId":"6031080","version":"1","preferredName":"Stage IIA Lung Cancer AJCC v8","longName":"6031080","preferredDefinition":"Stage IIA includes: T2b, N0, M0. T2b: Tumor measuring more than 4 cm but 5 cm or less in greatest dimension.  N0: No regional lymph node metastases. M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IIA Lung Cancer AJCC v8","conceptCode":"C136476","definition":"Stage IIA includes: T2b, N0, M0. T2b: Tumor measuring more than 4 cm but 5 cm or less in greatest dimension.  N0: No regional lymph node metastases. M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E83235F-79FB-751B-E053-F662850AF9DE","latestVersionIndicator":"Yes","beginDate":"2017-11-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"85CCBFAD-D11D-1C32-E053-F662850A75DF","beginDate":"2017-11-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-05","modifiedBy":"ONEDATA","dateModified":"2019-04-05","deletedIndicator":"No"},{"value":"IIB","valueDescription":"Stage IIB Lung Cancer AJCC v8","ValueMeaning":{"publicId":"6031078","version":"1","preferredName":"Stage IIB Lung Cancer AJCC v8","longName":"6031078","preferredDefinition":"Stage IIB includes: (T1a, N1, M0); (T1b, N1, M0); (T1c, N1, M0); (T2a, N1, M0); (T2b, N1, M0); (T3, N0, M0). T1a: Tumor measuring 1 cm or less in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. T1b: Tumor measuring more than 1 cm but 2 cm or less in greatest dimension. T1c: Tumor measuring more than 2 cm but 3 cm or less in greatest dimension. T2a: Tumor measuring more than 3 cm but 4 cm or less in greatest dimension. T2b: Tumor measuring more than 4 cm but 5 cm or less in greatest dimension. T3: Tumor measuring more than 5 cm but 7 cm or less in greatest dimension or directly invading any of the following: parietal pleura (PL3), chest wall (including superior sulcus tumors), phrenic nerve, parietal pericardium; or separate tumor nodule(s) in the same lobe as the primary. N0: No regional lymph node metastases. N1: Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension. M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IIB Lung Cancer AJCC v8","conceptCode":"C136477","definition":"Stage IIB includes: (T1a, N1, M0); (T1b, N1, M0); (T1c, N1, M0); (T2a, N1, M0); (T2b, N1, M0); (T3, N0, M0). T1a: Tumor measuring 1 cm or less in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. T1b: Tumor measuring more than 1 cm but 2 cm or less in greatest dimension. T1c: Tumor measuring more than 2 cm but 3 cm or less in greatest dimension. T2a: Tumor measuring more than 3 cm but 4 cm or less in greatest dimension. T2b: Tumor measuring more than 4 cm but 5 cm or less in greatest dimension. T3: Tumor measuring more than 5 cm but 7 cm or less in greatest dimension or directly invading any of the following: parietal pleura (PL3), chest wall (including superior sulcus tumors), phrenic nerve, parietal pericardium; or separate tumor nodule(s) in the same lobe as the primary. N0: No regional lymph node metastases. N1: Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension. M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E83235F-79D5-751B-E053-F662850AF9DE","latestVersionIndicator":"Yes","beginDate":"2017-11-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"85CCBFAD-D133-1C32-E053-F662850A75DF","beginDate":"2017-11-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-05","modifiedBy":"ONEDATA","dateModified":"2019-04-05","deletedIndicator":"No"},{"value":"IIIA","valueDescription":"Stage IIIA Lung Cancer AJCC v8","ValueMeaning":{"publicId":"6031076","version":"1","preferredName":"Stage IIIA Lung Cancer AJCC v8","longName":"6031076","preferredDefinition":"Stage IIIA includes: (T1a, N2, M0); (T1b, N2, M0); (T1c, N2, M0); (T2a, N2, M0); (T2b, N2, M0); (T3, N1, M0); (T4, N0, M0); (T4, N1, M0). T1a: Tumor measuring 1 cm or less in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. T1b: Tumor measuring more than 1 cm but 2 cm or less in greatest dimension. T1c: Tumor measuring more than 2 cm but 3 cm or less in greatest dimension. T2a: Tumor measuring more than 3 cm but 4 cm or less in greatest dimension. T2b: Tumor measuring more than 4 cm but 5 cm or less in greatest dimension. T3: Tumor measuring more than 5 cm but 7 cm or less in greatest dimension or directly invading any of the following: parietal pleura (PL3), chest wall (including superior sulcus tumors), phrenic nerve, parietal pericardium; or separate tumor nodule(s) in the same lobe as the primary. T4: Tumor measuring more than 7 cm or tumor of any size invading one or more of the following: diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, or carina; separate tumor nodule(s) in an ipsilateral lobe different from that of the primary. N0: No regional lymph node metastases. N1: Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension. N2: Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s). M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IIIA Lung Cancer AJCC v8","conceptCode":"C136479","definition":"Stage IIIA includes: (T1a, N2, M0); (T1b, N2, M0); (T1c, N2, M0); (T2a, N2, M0); (T2b, N2, M0); (T3, N1, M0); (T4, N0, M0); (T4, N1, M0). T1a: Tumor measuring 1 cm or less in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. T1b: Tumor measuring more than 1 cm but 2 cm or less in greatest dimension. T1c: Tumor measuring more than 2 cm but 3 cm or less in greatest dimension. T2a: Tumor measuring more than 3 cm but 4 cm or less in greatest dimension. T2b: Tumor measuring more than 4 cm but 5 cm or less in greatest dimension. T3: Tumor measuring more than 5 cm but 7 cm or less in greatest dimension or directly invading any of the following: parietal pleura (PL3), chest wall (including superior sulcus tumors), phrenic nerve, parietal pericardium; or separate tumor nodule(s) in the same lobe as the primary. T4: Tumor measuring more than 7 cm or tumor of any size invading one or more of the following: diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, or carina; separate tumor nodule(s) in an ipsilateral lobe different from that of the primary. N0: No regional lymph node metastases. N1: Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension. N2: Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s). M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E83235F-79AF-751B-E053-F662850AF9DE","latestVersionIndicator":"Yes","beginDate":"2017-11-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"85CCBFAD-D149-1C32-E053-F662850A75DF","beginDate":"2017-11-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-05","modifiedBy":"ONEDATA","dateModified":"2019-04-05","deletedIndicator":"No"},{"value":"IIIB","valueDescription":"Stage IIIB Lung Cancer AJCC v8","ValueMeaning":{"publicId":"6031074","version":"1","preferredName":"Stage IIIB Lung Cancer AJCC v8","longName":"6031074","preferredDefinition":"Stage IIIB includes: (T1a, N3, M0); (T1b, N3, M0); (T1c, N3, M0); (T2a, N3, M0); (T2b, N3, M0); (T3, N2, M0); (T4, N2, M0). T1a: Tumor measuring 1 cm or less in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. T1b: Tumor measuring more than 1 cm but 2 cm or less in greatest dimension. T1c: Tumor measuring more than 2 cm but 3 cm or less in greatest dimension. T2a: Tumor measuring more than 3 cm but 4 cm or less in greatest dimension. T2b: Tumor measuring more than 4 cm but 5 cm or less in greatest dimension. T3: Tumor measuring more than 5 cm but 7 cm or less in greatest dimension or directly invading any of the following: parietal pleura (PL3), chest wall (including superior sulcus tumors), phrenic nerve, parietal pericardium; or separate tumor nodule(s) in the same lobe as the primary. T4: Tumor measuring more than 7 cm or tumor of any size invading one or more of the following: diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, or carina; separate tumor nodule(s) in an ipsilateral lobe different from that of the primary. N2: Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s). N3: Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s). M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IIIB Lung Cancer AJCC v8","conceptCode":"C136480","definition":"Stage IIIB includes: (T1a, N3, M0); (T1b, N3, M0); (T1c, N3, M0); (T2a, N3, M0); (T2b, N3, M0); (T3, N2, M0); (T4, N2, M0). T1a: Tumor measuring 1 cm or less in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. T1b: Tumor measuring more than 1 cm but 2 cm or less in greatest dimension. T1c: Tumor measuring more than 2 cm but 3 cm or less in greatest dimension. T2a: Tumor measuring more than 3 cm but 4 cm or less in greatest dimension. T2b: Tumor measuring more than 4 cm but 5 cm or less in greatest dimension. T3: Tumor measuring more than 5 cm but 7 cm or less in greatest dimension or directly invading any of the following: parietal pleura (PL3), chest wall (including superior sulcus tumors), phrenic nerve, parietal pericardium; or separate tumor nodule(s) in the same lobe as the primary. T4: Tumor measuring more than 7 cm or tumor of any size invading one or more of the following: diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, or carina; separate tumor nodule(s) in an ipsilateral lobe different from that of the primary. N2: Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s). N3: Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s). M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E83235F-7989-751B-E053-F662850AF9DE","latestVersionIndicator":"Yes","beginDate":"2017-11-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"85CCBFAD-D15F-1C32-E053-F662850A75DF","beginDate":"2017-11-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-05","modifiedBy":"ONEDATA","dateModified":"2019-04-05","deletedIndicator":"No"},{"value":"IIIC","valueDescription":"Stage IIIC Lung Cancer AJCC v8","ValueMeaning":{"publicId":"6031072","version":"1","preferredName":"Stage IIIC Lung Cancer AJCC v8","longName":"6031072","preferredDefinition":"Stage IIIC includes: (T3, N3, M0); (T4, N3, M0). T3: Tumor measuring more than 5 cm but 7 cm or less in greatest dimension or directly invading any of the following: parietal pleura (PL3), chest wall (including superior sulcus tumors), phrenic nerve, parietal pericardium; or separate tumor nodule(s) in the same lobe as the primary. T4: Tumor measuring more than 7 cm or tumor of any size invading one or more of the following: diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, or carina; separate tumor nodule(s) in an ipsilateral lobe different from that of the primary. N3: Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s). M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IIIC Lung Cancer AJCC v8","conceptCode":"C136481","definition":"Stage IIIC includes: (T3, N3, M0); (T4, N3, M0). T3: Tumor measuring more than 5 cm but 7 cm or less in greatest dimension or directly invading any of the following: parietal pleura (PL3), chest wall (including superior sulcus tumors), phrenic nerve, parietal pericardium; or separate tumor nodule(s) in the same lobe as the primary. T4: Tumor measuring more than 7 cm or tumor of any size invading one or more of the following: diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, or carina; separate tumor nodule(s) in an ipsilateral lobe different from that of the primary. N3: Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s). M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E83235F-7963-751B-E053-F662850AF9DE","latestVersionIndicator":"Yes","beginDate":"2017-11-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"85CCBFAD-D175-1C32-E053-F662850A75DF","beginDate":"2017-11-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-05","modifiedBy":"ONEDATA","dateModified":"2019-04-05","deletedIndicator":"No"},{"value":"IVA","valueDescription":"Stage IVA Lung Cancer AJCC v8","ValueMeaning":{"publicId":"6031068","version":"1","preferredName":"Stage IVA Lung Cancer AJCC v8","longName":"6031068","preferredDefinition":"Stage IVA includes: (Any T, Any N, M1a); (Any T, Any N, M1b). M1a: Tumor with separate tumor nodule(s) in a contralateral lobe; tumor with pleural or pericardial nodules or malignant pleural or pericardial effusion. Most pleural (pericardial) effusions with lung cancer are a result of the tumor. In a few patients, however, multiple microscopic examinations of pleural (pericardial) fluid are negative for tumor, and the fluid is nonbloody and not an exudate. If these elements and clinical judgment dictate that the effusion is not related to the tumor, the effusion should be excluded as a staging descriptor. M1b: Tumor with single extrathoracic metastasis in a single organ (including involvement of a single nonregional node). (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IVA Lung Cancer AJCC v8","conceptCode":"C136483","definition":"Stage IVA includes: (Any T, Any N, M1a); (Any T, Any N, M1b). M1a: Tumor with separate tumor nodule(s) in a contralateral lobe; tumor with pleural or pericardial nodules or malignant pleural or pericardial effusion. Most pleural (pericardial) effusions with lung cancer are a result of the tumor. In a few patients, however, multiple microscopic examinations of pleural (pericardial) fluid are negative for tumor, and the fluid is nonbloody and not an exudate. If these elements and clinical judgment dictate that the effusion is not related to the tumor, the effusion should be excluded as a staging descriptor. M1b: Tumor with single extrathoracic metastasis in a single organ (including involvement of a single nonregional node). (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E83235F-7917-751B-E053-F662850AF9DE","latestVersionIndicator":"Yes","beginDate":"2017-11-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"85CCBFAD-D189-1C32-E053-F662850A75DF","beginDate":"2017-11-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-05","modifiedBy":"ONEDATA","dateModified":"2019-04-05","deletedIndicator":"No"},{"value":"IVB","valueDescription":"Stage IVB Lung Cancer AJCC v8","ValueMeaning":{"publicId":"6031066","version":"1","preferredName":"Stage IVB Lung Cancer AJCC v8","longName":"6031066","preferredDefinition":"Stage IVB includes: Any T, Any N, M1c. M1c: Tumor with multiple extrathoracic metastases in a single organ or in multiple organs. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IVB Lung Cancer AJCC v8","conceptCode":"C136484","definition":"Stage IVB includes: Any T, Any N, M1c. M1c: Tumor with multiple extrathoracic metastases in a single organ or in multiple organs. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E83235F-78F1-751B-E053-F662850AF9DE","latestVersionIndicator":"Yes","beginDate":"2017-11-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"85CCBFAD-D19D-1C32-E053-F662850A75DF","beginDate":"2017-11-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-05","modifiedBy":"ONEDATA","dateModified":"2019-04-05","deletedIndicator":"No"},{"value":"Occult carcinoma","valueDescription":"Occult Lung Cancer AJCC v8","ValueMeaning":{"publicId":"6031064","version":"1","preferredName":"Occult Lung Cancer AJCC v8","longName":"6031064","preferredDefinition":"Occult lung cancer includes: TX, N0, M0. TX: Primary tumor cannot be assessed. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Occult Lung Cancer AJCC v8","conceptCode":"C136468","definition":"Occult lung cancer includes: TX, N0, M0. TX: Primary tumor cannot be assessed. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E83235F-78CB-751B-E053-F662850AF9DE","latestVersionIndicator":"Yes","beginDate":"2017-11-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"85CCBFAD-D1B1-1C32-E053-F662850A75DF","beginDate":"2017-11-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-05","modifiedBy":"ONEDATA","dateModified":"2019-04-05","deletedIndicator":"No"},{"value":"0","valueDescription":"Stage 0 Lung Cancer AJCC v8","ValueMeaning":{"publicId":"6031096","version":"1","preferredName":"Stage 0 Lung Cancer AJCC v8","longName":"6031096","preferredDefinition":"Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ. Squamous cell carcinoma in situ (SCIS). Adenocarcinoma in situ (AIS): adenocarcinoma with pure lepidic pattern, 3 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage 0 Lung Cancer AJCC v8","conceptCode":"C136469","definition":"Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ. Squamous cell carcinoma in situ (SCIS). Adenocarcinoma in situ (AIS): adenocarcinoma with pure lepidic pattern, 3 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E83235F-7B2B-751B-E053-F662850AF9DE","latestVersionIndicator":"Yes","beginDate":"2017-11-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5E83235F-7B44-751B-E053-F662850AF9DE","beginDate":"2017-11-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-21","modifiedBy":"ONEDATA","dateModified":"2017-11-21","deletedIndicator":"No"},{"value":"IV","valueDescription":"Stage IV Lung Cancer AJCC v8","ValueMeaning":{"publicId":"6031070","version":"1","preferredName":"Stage IV Lung Cancer AJCC v8","longName":"6031070","preferredDefinition":"Stage IV includes: IVA: (Any T, Any N, M1a); (Any T, Any N, M1b); IVB: (Any T, Any N, M1c). M1a: Tumor with separate tumor nodule(s) in a contralateral lobe; tumor with pleural or pericardial nodules or malignant pleural or pericardial effusion. Most pleural (pericardial) effusions with lung cancer are a result of the tumor. In a few patients, however, multiple microscopic examinations of pleural (pericardial) fluid are negative for tumor, and the fluid is nonbloody and not an exudate. If these elements and clinical judgment dictate that the effusion is not related to the tumor, the effusion should be excluded as a staging descriptor. M1b: Tumor with single extrathoracic metastasis in a single organ (including involvement of a single nonregional node). M1c: Tumor with multiple extrathoracic metastases in a single organ or in multiple organs. (AJCC 8th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IV Lung Cancer AJCC v8","conceptCode":"C136482","definition":"Stage IV includes: IVA: (Any T, Any N, M1a); (Any T, Any N, M1b); IVB: (Any T, Any N, M1c). M1a: Tumor with separate tumor nodule(s) in a contralateral lobe; tumor with pleural or pericardial nodules or malignant pleural or pericardial effusion. Most pleural (pericardial) effusions with lung cancer are a result of the tumor. In a few patients, however, multiple microscopic examinations of pleural (pericardial) fluid are negative for tumor, and the fluid is nonbloody and not an exudate. If these elements and clinical judgment dictate that the effusion is not related to the tumor, the effusion should be excluded as a staging descriptor. M1b: Tumor with single extrathoracic metastasis in a single organ (including involvement of a single nonregional node). M1c: Tumor with multiple extrathoracic metastases in a single organ or in multiple organs. (AJCC 8th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E83235F-793D-751B-E053-F662850AF9DE","latestVersionIndicator":"Yes","beginDate":"2017-11-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"860BEFA9-E88C-5813-E053-F662850A6764","beginDate":"2019-04-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-08","modifiedBy":"ONEDATA","dateModified":"2019-04-08","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6686911","version":"1","preferredName":"Lung Cancer by AJCC v8 Stage Stage Grouping Stage","preferredDefinition":"A term that refers to the staging of lung cancer, following the rules of the TNM AJCC v8 classification system. This staging system derives from analyses of the new retrospective and prospective databases of the International Association for the Study of Lung Cancer (IASLC). These databases contain information on patients diagnosed with lung cancer from 1999 to 2010 originating from 35 different databases in 16 countries around the world. This staging system applies to carcinomas of the lung, including non-small cell and small cell carcinomas, and bronchopulmonary carcinoid tumors. It does not apply to sarcomas or other rare tumors of the lung. (from AJCC 8th Ed.):An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.:The extent of a cancer in the body. Staging is usually based on the size of the tumor, whether lymph nodes contain cancer, and whether the cancer has spread from the original site to other parts of the body.","longName":"C136467:C38027:C16899","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lung Cancer by AJCC v8 Stage","conceptCode":"C136467","definition":"A term that refers to the staging of lung cancer, following the rules of the TNM AJCC v8 classification system. This staging system derives from analyses of the new retrospective and prospective databases of the International Association for the Study of Lung Cancer (IASLC). These databases contain information on patients diagnosed with lung cancer from 1999 to 2010 originating from 35 different databases in 16 countries around the world. This staging system applies to carcinomas of the lung, including non-small cell and small cell carcinomas, and bronchopulmonary carcinoid tumors. It does not apply to sarcomas or other rare tumors of the lung. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Stage Grouping","conceptCode":"C38027","definition":"An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm Stage","conceptCode":"C16899","definition":"The extent of a cancer in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"85CCBFAD-CF3D-1C32-E053-F662850A75DF","latestVersionIndicator":"Yes","beginDate":"2019-04-05","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-04-05","modifiedBy":"ONEDATA","dateModified":"2019-04-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"5E83235F-78A5-751B-E053-F662850AF9DE","latestVersionIndicator":"Yes","beginDate":"2017-11-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-21","modifiedBy":"TAYLORT","dateModified":"2019-04-08","changeDescription":"4/8/19 Released/NRG QC. 4-5-19 edits / AJCC Ed. 8 and FG style guide; tmt.  11/21/17 tt created for standardization; associated with CS/CSI.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5506111","version":"1","longName":"Lung","context":"MCL","ClassificationSchemeItems":[{"publicId":"7781146","version":"1","longName":"Lung PCA Pilot","context":"MCL"},{"publicId":"5858017","version":"1","longName":"Lung Core","context":"MCL"}]},{"publicId":"5574838","version":"1","longName":"Staging/Extent of Disease","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"6005920","version":"1","longName":"AJCC Edition 8","context":"NCI Standards"},{"publicId":"10000598","version":"1","longName":"Lung","context":"NCI Standards"}]},{"publicId":"6437797","version":"1","longName":"Pre-Cancer Atlas Pilot","context":"MCL","ClassificationSchemeItems":[{"publicId":"7001792","version":"1","longName":"Lung PCA Pilot","context":"MCL"}]}],"AlternateNames":[{"name":"MCL","type":"USED_BY","context":"MCL"},{"name":"ECOG-ACRIN","type":"USED_BY","context":"ECOG-ACRIN"},{"name":"ajcc_8_lung_disease_stage","type":"MCL Alt Name","context":"MCL"}],"ReferenceDocuments":[{"name":"Disease stage","type":"Preferred Question Text","description":"Disease stage","url":null,"context":"NCI Standards"},{"name":"MCL-PCA-1","type":"Alternate Question Text","description":"Path Stage","url":null,"context":"MCL"},{"name":"OPEN","type":"Alternate Question Text","description":"Stage","url":null,"context":"ECOG-ACRIN"},{"name":"MCL-PCA-Lung-1","type":"Alternate Question Text","description":"American Joint Committee on Cancer neoplasm disease stage code","url":null,"context":"MCL"},{"name":"MCL-Template Name","type":"Data Collection Template","description":"lung_v0_2021_08_25-metrics.xlsx","url":"https://mcl.nci.nih.gov/resources/standards/mcl-cdes","context":"MCL"}],"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"5E8203E4-BF06-78BF-E053-F662850A3B97","latestVersionIndicator":"Yes","beginDate":"2017-11-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-21","modifiedBy":"COLBERTM","dateModified":"2021-09-13","changeDescription":"9/10/21 mr Added alt name, AQT, alt def, ref doc. CSI MCL Lung Core. Per MCL DD.   4/8/19 Released/NRG QC. 4-5-19 edits / AJCC Ed. 8 and FG style guide; tmt. 11/21/17 tt created for standardization; associated with CS/CSI.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}